We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
101
Sutro Biopharma
STRO
$401M
$4.98M 0.19%
64,127
– –
MTD icon
102
Mettler-Toledo International
MTD
$28.6B
$4.93M 0.19%
6,123
– –
MOH icon
103
Molina Healthcare
MOH
$10.2B
$4.9M 0.19%
+27,536
New +$4.69M
TBPH icon
104
Theravance Biopharma
TBPH
$874M
$4.8M 0.18%
228,836
– –
XNCR icon
105
Xencor
XNCR
$1.5B
$4.8M 0.18%
148,231
– –
A icon
106
Agilent Technologies
A
$39.1B
$4.64M 0.18%
52,525
– –
ALLK
107
DELISTED
Allakos
ALLK
$4.63M 0.18%
64,397
– –
GBT
108
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.53M 0.17%
71,759
-46,324
-39% -$3.18M
PVLA
109
Palvella Therapeutics
PVLA
$1.99B
$4.49M 0.17%
18,116
– –
ARDX icon
110
Ardelyx
ARDX
$1.22B
$4.21M 0.16%
607,698
– –
DOC icon
111
Healthpeak Properties
DOC
$15.1B
$4.14M 0.16%
150,392
– –
SAGE
112
DELISTED
Sage Therapeutics
SAGE
$4M 0.15%
96,211
– –
XLRN
113
DELISTED
Acceleron Pharma
XLRN
$3.87M 0.15%
40,606
– –
AMED
114
DELISTED
Amedisys
AMED
$3.85M 0.15%
+19,395
New +$3.62M
EDIT icon
115
Editas Medicine
EDIT
$396M
$3.85M 0.15%
130,201
– –
EXAS
116
DELISTED
Exact Sciences
EXAS
$3.83M 0.15%
44,015
+20,882
+90% +$1.67M
ABMD
117
DELISTED
Abiomed Inc
ABMD
$3.81M 0.15%
15,794
-13,722
-46% -$2.76M
SNN icon
118
Smith & Nephew
SNN
$13.3B
$3.79M 0.14%
99,560
– –
RVTY icon
119
Revvity
RVTY
$12.6B
$3.78M 0.14%
38,494
– –
TAK icon
120
Takeda Pharmaceutical
TAK
$54.6B
$3.77M 0.14%
210,146
– –
MNTA
121
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$3.72M 0.14%
111,768
+20,452
+22% +$651K
ICPT
122
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.69M 0.14%
77,067
+42,653
+124% +$3.29M
DCPH
123
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.67M 0.14%
61,370
– –
CHRS icon
124
Coherus Oncology
CHRS
$217M
$3.63M 0.14%
203,103
+91,440
+82% +$1.55M
TRIL
125
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.63M 0.14%
448,049
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.